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I believe that economic evaluation plays an important 
and essential role in the market access decisions of 
pharmaceutical treatments for cancer patients with a 
short life expectancy. Increasing health care 
expenditures, a rapid introduction of new medical 
technologies has led to a growing interest in 
information from economic evaluations for decision 
making about resource allocation in health care. 
Economic evaluations can provide valuable 
information in relation  to drug use, other healthcare 
intervention/programmes, and investments in 
research and new technologies. However, there are 
currently the most widely used pricing and 
reimbursement decisions for new drugs and health 
technology assessments of cancer patients.1  
 
An example of economic evaluation in market access 
decisions of pharmaceutical treatments for cancer 
patients with short life expectancy in the UK is value-
based pricing (VBP), which is a potential solution to 
barriers to accessing new expensive drugs for 
healthcare providers, and to improve market 
access/reimbursement for the industry. Examples of 
VBP include cost-effectiveness analysis (CEA) and 
therapeutic added value (TAV). CEA tries to 
determine the value of spending on medicines or 
policies that are returned to sufferers, such as longer 
life and better quality of life.2 
 
The CEA of drugs is assessed for reimbursement price 
using QALY and incremental costs relative to existing 
treatments. QALYs are calculated by multiplying how 
much a given treatment will lengthen a patient's life 
by improving the quality. CEA for drugs is regarded 
by economists as being, in theory, compatible with 
efficient resource allocation.   TAV assessments 
typically include a relationship with other instituted 
medications in the same class used in the standard of 
care. Higher costs settled for improved health or 
different values recognized by payers.2  
 
Health economics and outcomes researchers 
generally measure value using the CEA tool with the 
QALY as the health gain measure.3 Most health  
 
technology assessment (HTA) systems base their 
decision-making on QALY. Health care systems 
should recognize a wide range of cost savings in the 
present and the future if they result directly from 
interventions of interest, as recommended by the 
second panel on cost-effectiveness in health and 
medicine.3  
 
The benefit is measured from the patient's 
perspective addressed by healthcare technology in 
question. Ideally, QALY can be used to measure the 
health gains of any technology. Costs and QALYs 
frequently form the basis of CEA value assessments. 
The QALY continues to be seen as a measure of the 
medical benefits to be used in population decision-
making.3  
 
Figure 1 shows the incorporation of additional 
elements of value into CEA (the preferred method of 
showing value), where twelve potential elements of 
value are considered. Four of them— productivity, 
net costs, adherence-improving factors, and QALY—
are traditionally included in value assessments. Eight 
others currently have novelty in economic 
assessments, such as disease severity, the value of 
hope, fear of contagion, reducing uncertainty, 
insurance value,  equity, real option value, and 
scientific spillover. Many of these theoretical 
elements of value are well known and are ready for 
incorporation in value assessments, with the 
difference of two exceptions: scientific spillover and 
equity, which so far have not the required attention, 
possibly because they require more consensus and 
theoretical improvement.4 These elements are 
important for the economic evaluation of end-of-life 
care patients. 
 
Up to £50,000/QALY can be spent on end-of-life 
pharmaceutical products. It differs from other 
pharmaceutical products for the general population, 
which have a lower value, such as £5000/QALY or 
much less. For example, the management of chronic 
pain remains a challenge for physicians. Opioids are 
the main source of treatment for chronic severe pain. 
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A recent meta-analysis showed that tapentadol PR 
(TAP PR) and oxycodone/naloxone (OXN) both 
drugs have a better tolerability profile than a 
traditional opioid, such as oxycodone CR. OXN 
gained in one year 0.29 QALYs compared to its 
counterpart OXY CR.5 
 
End-of-life care drugs have a higher QALY compared 
to other pharmaceutical products for the general 
population. Many innovative end-of-life drugs are 
biologics, such as monoclonal antibodies that have a 
high cost of production. Previous rigorous research 
and clinical trials have made them even more 
expensive. Therefore, their QALY thresholds are 
much higher than those of other pharmaceutical 
products for the general population.  
 
I agree with the idea of the existence of an ‘end-of-
life’ premium for such treatments with monthly 
affordable price contributions to health insurance 
institutions that agree to cover any palliative care,  
 
medical treatment, or diagnostic interventions for 
end-of-life care of patients.  This would facilitate the 
use of a large amount of money to pay for drugs and 
may release the NHS hardship that would otherwise 
have had to contribute to the treatment using the 
highest QALY thresholds to purchase medicines for 
the pharmaceutical industry.  
 
The insurance would pay for drugs that give an extra 
few months of life expectancy to terminally ill 
patients, and it helps to prepare patients’ families 
psychologically for the short span of life of their loved 
ones. On the other hand, for a shorter life span period 
and overall survival insurance could also contribute 
to other alternative medicine care to decrease the 
burden of end-of-life care for patients and their 
families.  
 
In January 2019, a voluntary scheme for branded 
medicines and access (VPAS) was introduced to 
replace the UK Pharmaceutical Price Regulation 
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Figure 1. Twelve elements of value incorporated into CEA.4 
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Scheme (PPRS). This scheme aims to strike a balance 
between supporting innovation in the 
pharmaceutical industry, helping to get the most 
cost-effective medicines to patients as quickly as 
possible, and ensuring complete predictability of 
spending for the entire branded medicines bill for the 
NHS. The VPAS means that the branded medicines 
bill will not grow by more than 2% in any of the next 
five years.6 
  
The government predicts that this will end in profits 
of £ 930 m. Nevertheless, further steps to expedite 
decision-making on new medications suggest that 
they could reach sufferers up to six months more 
quickly than today. The aforementioned low rate of 
growth, coupled with new cost controls launched by 
NHS England on new innovative medicines, signifies 
that the pharmaceutical division is 'not dancing for 
satisfaction' over the deal. However, it provides 
stability and predictability for the United Kingdom 
sector, where the doubts of Brexit remain to endanger 
the overall UK marketability.7  
 
The cost-benefit evaluation of health interventions 
should be analyzed in all modalities of treatment, 
whether palliative or pharmaceutical. It is essential to 
assess differences, if any, that may exist in the 
economic evaluation of such treatments. Likewise, 
QALY as a part of CEA is assessed for all treatments 
and health interventions as an example that 
economic evaluation of non-pharmaceutical 
interventions/initiatives in palliative care or end-of-
life care should not differ from pharmaceutical 
treatments. 
 
I consider that buying expensive drugs to extend end-
of-life patients should also be linked to the ability of 
the drugs to improve the quality of life of those with 
end-of-life diseases. New policies should be 
developed in the application of more palliative care, 
pain management, and use of alternative and 
traditional medicine modalities to ameliorate the 
suffering of many of these end-of-life conditions 
versus increasing the QALY threshold for purchasing 
expensive drugs, with little information on extending 
or improving quality of life. It is understood that all 
deserve the best treatment at any stage of their 
disease. This finding is significant for patients with 
rare cancers. Therefore, the use of orphan drugs is 
essential. However, monetary resources should be 
allocated to improve the existing programs on 
vaccinations in childhood. In addition, nationwide  
 
vaccination programs should be implemented to 
prevent the emergence of diseases. The NHS should 
achieve comprehensive cancer screening programs 
for the most common cancers that affect humans as 
breast, lung, prostate, and colorectal cancers, or 
purchasing or developing new treatments for new 
diseases such as COVID-19. Public perceptions can be 
aligned to NICE policies by recommendations on 
lower prices of medicines for the end of life and 
improve people's quality of life. A lower QALY 
threshold for end-of-life drugs is made cheaper and 
more widely available, with easy access to the sick. 
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